Mutual of America Capital Management LLC Sells 3,649 Shares of Repligen Co. (NASDAQ:RGEN)

Mutual of America Capital Management LLC trimmed its position in Repligen Co. (NASDAQ:RGENFree Report) by 9.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,214 shares of the biotechnology company’s stock after selling 3,649 shares during the quarter. Mutual of America Capital Management LLC owned 0.06% of Repligen worth $5,599,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of RGEN. Financial Gravity Asset Management Inc. acquired a new position in Repligen during the second quarter worth $3,101,000. Fortis Capital Advisors LLC acquired a new stake in shares of Repligen in the fourth quarter valued at $35,000. Park Place Capital Corp increased its stake in shares of Repligen by 90.2% in the third quarter. Park Place Capital Corp now owns 253 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 120 shares in the last quarter. Signaturefd LLC increased its stake in shares of Repligen by 44.1% in the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 86 shares in the last quarter. Finally, International Assets Investment Management LLC acquired a new stake in shares of Repligen in the third quarter valued at $51,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Trading Up 0.5 %

Repligen stock opened at $205.00 on Monday. The firm has a market capitalization of $11.45 billion, a P/E ratio of 100.99, a PEG ratio of 4.76 and a beta of 1.04. Repligen Co. has a 1 year low of $110.45 and a 1 year high of $208.16. The business has a 50-day moving average of $179.97 and a 200-day moving average of $165.70.

Wall Street Analysts Forecast Growth

RGEN has been the subject of a number of research reports. KeyCorp lowered their target price on Repligen from $240.00 to $210.00 and set an “overweight” rating for the company in a research note on Wednesday, November 1st. Royal Bank of Canada lowered their price objective on Repligen from $207.00 to $200.00 and set an “outperform” rating for the company in a research report on Wednesday, November 1st. UBS Group lowered their price objective on Repligen from $210.00 to $170.00 and set a “buy” rating for the company in a research report on Thursday, November 2nd. JPMorgan Chase & Co. lifted their price objective on Repligen from $170.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 20th. Finally, Stifel Nicolaus lowered their price objective on Repligen from $200.00 to $165.00 and set a “buy” rating for the company in a research report on Wednesday, November 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Repligen presently has an average rating of “Moderate Buy” and a consensus target price of $191.50.

Check Out Our Latest Stock Report on RGEN

Repligen Company Profile

(Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Further Reading

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.